Untitled

HealthTrust presents…“Neonatal Abstinence Syndrome”

Download a copy of this content.

Access the recording.

Supportive care for treating Neonatal Abstinence Syndrome (NAS) includes providing a gentle, soothing environment, limiting exposure to lights and noise, and adequate nutrition, among other measures. Pharmacologic care for NAS treatment consists of the use of opioids, such as oral morphine or methadone. Adjunctive therapy consists of phenobarbital and clonidine, in addition to the use of opioids. This presentation will review the mechanism, presentation and common medications used to treat NAS. The presenter will detail recent studies that compare primary and adjunctive treatment options, including evidence describing the use of sublingual buprenorphine to treat infants who have NAS. It has been associated with significant reductions in the duration of treatment and hospitalization. Additionally, the session will focus on safety concerns associated with the use of the medications used for NAS treatment.

Learning Objectives

At the end of this session, participants should be able to…

1. Define the mechanism and clinical presentation of NAS
2. List advantages and limitations of assessment tools utilized for NAS
3. Recognize recommended treatment options for NAS
4. Discuss adjunctive therapies used for NAS
5. State important safety and efficacy parameters associated with the current treatment options

Speaker:

Dhara D. Shah, PharmD, PGY-1 Resident at Atlantic Health System

Target audience: Pharmacy

Continuing education info: This program is approved for CPEs by the Accreditation Council for Pharmacy Education (ACPE). Attendees of the live program may earn 1.0 CPE Contact Hours. Belmont University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The ACPE Universal Activity Number for this activity is
0863-9999-18-011-L04-P. The activity will provide 1 hour (.1 CEUs) of continuing education credit to pharmacists who attend the webinar and complete the online evaluation.

There is no fee associated with this program.